Sign in

You're signed outSign in or to get full access.

Joseph W. Marshall, III

Director at SIGA TECHNOLOGIES
Board

About Joseph W. “Chip” Marshall, III

Independent director of SIGA since 2009; age 72. Former President & CEO of Temple University Health System with a legal and healthcare administration background (B.A. and J.D., Temple University). Currently Audit Committee Chair and deemed an “audit committee financial expert.” Attended at least 75% of Board and committee meetings in 2024; Board met 13 times and all directors attended the 2024 annual meeting .

Past Roles

OrganizationRoleTenureCommittees/Impact
Temple University Health SystemPresident & CEO2001–2008Led network operations and finances
Temple University Health SystemChair2000–2007; returned 2018Governance oversight, strategic direction
Goldman & Marshall P.C. (Philadelphia)Founding PartnerPre-2000Corporate healthcare law expertise
Pennsylvania State Ethics CommissionCommissioner; Chair (part of tenure)1980s–early 1990sEthics oversight; public integrity
Federal Medicaid CommissionMember2005–2006Federal policy advisory contributions
Pennsylvania Gaming Control BoardMember2004–2006Regulatory and compliance oversight

External Roles

OrganizationRoleTenureNotes
Gaming and Leisure Properties, Inc. (GLPI)Lead Independent DirectorCurrentPublic company board leadership
Maxim Healthcare ServicesDirectorCurrentPrivate company director
Fox Chase Comprehensive Cancer CenterBoard ChairCurrentHealthcare governance leader
Chestnut Hill Hospital (Philadelphia)Board ChairCurrentHospital board leadership

Board Governance

  • Committee assignments: Audit Committee Chair; Nominating & Corporate Governance Committee member .
  • Independence: Board determined Marshall independent under Nasdaq rules; all committee members meet heightened independence standards .
  • Expertise: Identified by the Board as an “audit committee financial expert” under SEC rules .
  • Attendance and engagement: Board met 13 times in 2024; each director attended at least 75% of Board/committee meetings and all directors attended the 2024 annual meeting. Independent directors hold regular executive sessions .
  • Board leadership structure: No standing Chair or Lead Independent Director; committee chairs rotate as de facto lead during executive sessions—potential governance risk in contested situations .

Fixed Compensation

ComponentAmountVesting/TimingNotes
Annual Director Retainer (member)$45,000Quarterly, in arrearsStandard for all non-employee directors
Audit Committee Chair$20,000Quarterly, in arrearsMarshall is Chair
Nominating & Corporate Governance Committee Member$5,000Quarterly, in arrearsMarshall is member
Meeting FeesNone disclosedNot part of policy
Marshall – 2024 Director CompensationAmountNotes
Fees Earned/Paid in Cash$71,250 Reflects committee roles
Stock Awards (RSUs grant-date value)$150,000 Annual RSU grant at Annual Meeting
All Other Compensation (Dividend Equivalents)$14,827 Paid upon RSU vesting
Total$236,077

Performance Compensation

Equity ComponentGrant PolicyVestingSettlement Mix
Annual RSUs (directors)$150,000 grant value at Annual MeetingVests at next Annual MeetingUp to 30% cash; ≥70% stock
Initial Option Award (upon appointment)25,000 optionsVests upon grant dateStandard for new directors
Marshall – Current Year RSU DetailShares/UnitsVesting DateCash-Settled Portion
RSUs outstanding attributable to 2024 grant cycle13,359 June 10, 2025 5,725 RSUs to be settled in cash

No director performance metrics (e.g., revenue, EBITDA, TSR) are tied to director pay; director equity grants are time-based per policy .

Other Directorships & Interlocks

EntityTypeRelationship to SIGAInterlock/Conflict Note
Gaming and Leisure Properties, Inc.PublicUnrelated industry (gaming REIT)No related-party transactions disclosed involving Marshall
Maxim Healthcare ServicesPrivateUnrelated to SIGA contractsNo related-party transactions disclosed involving Marshall
  • Related-party backdrop at SIGA: HQ lease with MacAndrews & Forbes (principal stockholder) and a former director’s advisory firm (Knisely) retained by SIGA; Board assessed independence of directors with M&F ties (Nemirovsky, Durnan). No Marshall-specific related-party transactions disclosed .

Expertise & Qualifications

  • Healthcare system leadership and governance (Temple Health; Fox Chase; Chestnut Hill) .
  • Legal training and ethics oversight (J.D.; PA State Ethics Commission chair) .
  • Public sector experience (Federal Medicaid Commission; PA Gaming Control Board) .
  • Audit and financial governance expertise; designated audit committee financial expert .

Equity Ownership

HolderBeneficial Shares% OutstandingComponents and Notes
Joseph W. Marshall III229,642 <1% Includes 13,359 RSUs vesting on June 10, 2025; excludes 5,725 RSUs to be cash-settled on June 10, 2025
  • Options exercisable within 60 days: none disclosed for Marshall (footnote lists only RSUs) .
  • Hedging/short-selling: Company policy prohibits short-selling and restricts hedging without preclearance .
  • Ownership guidelines: Company has no formal written common stock ownership requirements (disclosed for executives; no separate director policy disclosed) .

Governance Assessment

  • Positives:

    • Long-tenured, independent director with deep healthcare and legal credentials; strong committee leadership as Audit Chair and SEC-designated financial expert—supports financial reporting integrity .
    • Solid engagement: ≥75% attendance; Board met frequently in 2024; independent director executive sessions occur regularly—indicates oversight rigor .
    • Director pay structure balanced between cash retainer and equity RSUs; settlement at least 70% stock promotes alignment (even with partial cash settlement) .
  • Watch items/RED FLAGS:

    • No permanent Chair or Lead Independent Director—committee-chair rotation may dilute accountability during sensitive governance events .
    • Related-party environment (M&F HQ lease; services from former director’s advisory firm); while independence was affirmed, continued vigilance is warranted by Audit Committee (which Marshall chairs) .
    • Director equity has partial cash settlement allowance (up to 30%), modest alignment impact versus full equity settlement; Marshall’s footnote indicates cash-settled RSUs in 2025 .